Brief: MaaT Pharma Says Presents Promising Detailed Results From Completed Phase 1B Trial With MaaT033
11/12/2022 15:08
Dec 11 (Reuters) - Maat Pharma SA MAAT.PA :
* MAAT PHARMA PRESENTS PROMISING DETAILED RESULTS FROM
COMPLETED
PHASE 1B TRIAL WITH MAAT033 AT THE 64TH ASH ANNUAL MEETING
* RESULTS OF STUDY EVALUATING TOLERATED DOSE OF MAAT033 IN
PATIENTS WITH AML SHOWED INITIAL ENGRAFTMENT OF BENEFICIAL
BACTERIAL SPECIES
Source text for Eikon: ID:nBw4ZGSKka
Further company coverage: MAAT.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maat Pharma SA
See all newsBrief: MaaT Pharma Says FDA Indicates No Additional Nonclinical Studies Required For MaaT034 Safety
France's MaaT Pharma H1 operating loss widens on higher R&D costs
Brief: MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)
France's MaaT Pharma 2025 revenue rises 40.7% but misses expectations
Brief: MaaT Pharma Says Xervyteg Under EMA Review, Decision Expected In H2 2026